Autopsy report · NCT00430014

Study of Atiprimod Treatment for Patients With Advanced Cancer

“Sponsor Withdrew”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 11 months after it had already started.
• Ran for about 6 years 11 months before it stopped.
• 28 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Advanced Cancer

Interventions

Atiprimod

Participants

28

Sites

1

Countries

United States

Trials that died the same way

• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (96% match in meaning)
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
  “Withdrawn by sponsor” (94% match in meaning)
• Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
  “Sponsor withdrew support” (93% match in meaning)
• Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder
  “Sponsor withdrew funding” (90% match in meaning)
• Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection
  “Sponsored withdrew” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.